Pregnancy and Postpartum CGM in Gestational Diabetes

This observational study is looking at how continuous glucose monitor (CGM) data from the Dexcom G7 can help predict blood sugar levels after pregnancy in women who had gestational diabetes (diabetes during pregnancy). We want to see if CGM readings during your third trimester and up to 14 days after giving birth can tell us if you might have abnormal blood sugars later on. The main goal is to see how well CGM data can identify women who have a specific blood sugar result (TIR <96%) up to 12 weeks after delivery. We are looking for about 40 women who are 18 or older, have gestational diabetes in their current pregnancy, and are already prescribed a Dexcom G7. This study is currently recruiting participants.

Study design
This is an observational study involving about 40 women. It is not a randomized trial.
What's involved
You will use your Dexcom G7 as usual during pregnancy and wear one sensor after delivery. You will also have a standard blood sugar test (OGTT) around 6 weeks postpartum and complete a remote questionnaire after that test.
Compensation
Not stated in the trial record.
Follow-up
Participants are followed up to 12 weeks postpartum for the primary endpoint.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07174245

Pregnancy and Postpartum CGM in GDM

Recruiting
Not specifiedAges 18+Observational
Icahn School of Medicine at Mount Sinai
~40 participants
Updated 2026-07-08 on ClinicalTrials.gov
What's tested:continuous glucose monitor

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of postpartum TIR <96%
Measured over up to 12 weeks postpartum
Gestational Diabetes
1 sites across 1 states
New York1
  • Grenye O'Malley, MD · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine at Mount Sinai

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of gestational diabetes during current pregnancy
age 18 or older
prescribed Dexcom G7

Exclusion

Pregestational diabetes
known skin adhesive allergy which inhibits ongoing use of CGM
chronic oral steroid use.
  • Sensitivity of postpartum TIR <96%up to 12 weeks postpartum

    Sensitivity of postpartum time in range (TIR) \<96% to predict dysglycemia on OGTT. Range 70-180 mg/dL. Sensitivity determined by true positives of TIR \<96% and abnormal OGTT and false negatives would be TIR \<96% with normal OGTT.